Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance

BACKGROUND Dimethyl fumarate (DMF), a disease-modifying therapy for multiple sclerosis (MS), causes lymphopenia in a fraction of patients. The clinical significance of this is unknown. Several cases of progressive multifocal leukoencephalopathy in lymphopenic fumarate-treated patients have raised concerns about drug safety. Since lymphocytes contribute to… (More)
  • Blog articles referencing this paper

  • Presentations referencing similar topics